Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking

British Journal of Clinical Pharmacology

Volumn 43, Issue 3, 1997, Pages 259-267

  Benowitz, N L ^a   Zevin, S ^b   Jacob III, P ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

3 hydroxycotinine; bioavailability; cigarette smoking; cotinine; kinetics; metabolism; nasal spray; nicotine; transdermal

Indexed keywords

3' HYDROXYCOTININE; COTININE; DRUG METABOLITE; NICOTINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG MONITORING; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031050903     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1997.00566.x     Document Type: Article

References (30)

1. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139-142.
2. Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? Br Med J 1994; 308: 21-26.
3. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994; 271: 1940-1947.
4. Sutherland G, Stapleton JA, Russell MAH et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324-329.
5. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. Arch Int Med 1994; 154: 2567-2572.
6. Schneider NG, Olmstead R, Mody FV et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90: 1671-1682.
7. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. JAMA 1991; 266: 3133-3138.
8. Hurt RD, Dale LC, Offord KP, et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther 1993; 54: 98-106.
9. Benowitz NL, Chan K, Denaro CP, Jacob P, III. Stable isotope method for studying transdermal drug absorption: The nicotine patch. Clin Pharmacol Ther 1991; 50: 286-293.
10. Benowitz NL, Jacob P, III, Olsson P, Johansson CJ. Intravenous nicotine retards transdermal absorption of nicotine: Evidence of blood flow-limited percutaneous absorption. Clin Pharmacol Ther 1992; 52: 223-230.
11. Johansson CJ, Olsson P, Bende M, Carlsson T, Gunnarsson PO. Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 1991; 41: 585-588.
12. Benowitz NL, Jacob P, III. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 1984; 35: 499-504.
13. Benowitz NL, Jacob P, III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994; 56: 483-493.
14. Jacob P, III, Wilson M, Benowitz NL. Improved gas chromatographic method for determination of nicotine and cotinine in biologic fluids. J Chromatogr 1981; 222: 61-70.
15. Jacob P, III, Shulgin A, Yu L, Benowitz NL. Determination of the nicotine metabolite trans-3′-hydroxycotinine in smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J Chromatogr 1992; 583: 145-154.
16. 2 in humans. Biological Mass Spectrometry 1991; 20: 247-252.
17. Jacob P, III, Benowitz NL, Shulgin AT. Synthesis of optically pure deuterium-labelled nicotine, nornicotine and cotinine. J Labelled Comp Radiopharmaceut 1988; 25: 1117-1128.
18. Benet LZ, Galleazzi RL. Noncompartmental determination of the steady state volume of distribution. J Pharm Sci 1979; 68: 1071-1074.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-310.
20. Gourlay SG, Benowitz NL, Forbes AF, McNeill JJ. Determinants of plasma levels of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment. Eur J Clin Pharmacol, 1997; in press.
21. Benowitz NL, Jacob P, III, Kozlowski L, Yu L. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide exposure. N Engl J Med 1986; 314; 1310-1313.
22. Benowitz NL. Nicotine replacement therapy. What has been accomplished - can we do better? Drugs 1993; 45: 157-170.
23. Neurath GB, Dunger M, Orth D, Pein FG. Trans-3′-hydroxycotinine as a main metabolite in urine of smokers. Int Arch Occup Environ Hlth 1987; 59: 199-201.
24. Jacob P, III, Benowitz NL, Shulgin AT. Recent studies of nicotine metabolism in humans. Pharmacol Biochem Behav 1988; 41: 474-479.
25. Byrd GD, Chang K, Greene JM, deBethizy JD. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers. Drug Metab Dispos 1992; 20: 192-197.
26. Benowitz NL, Jacob P, III, Fong I, Gupta S. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994; 268: 296-303.
27. Caldwell WS, Greene JM, Byrd GD, Chang KM, Uhrig MS, deBethizy JD. Characterization of the glucuronide conjugate of cotinine: A previously unidentified major metabolite of nicotine in smokers' urine. Chem Res Toxicol 1992; 5: 280-285.
28. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 1995; 274: 1353-1358.
29. Sachs DP, Benowitz NL, Bostrum AG, Hansen MD. Percent serum replacement and success of nicotine patch therapy. Am J Resp Crit Care Med 1995; 151: A688.
30. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alc Depend 1993; 33: 23-29.